Vivax malaria infections acquired by the American serviceman in the South Pacific area are characterized by a tendency to repeated recurrences, and in this respect present a major problem. Some men are now entering their fourth year since becoming infected and are continuing to relapse at almost monthly intervals. Little difficulty has been experienced in interrupting each acute attack, but irrespective of the amount of any drug, or the duration of its administration, it has not been possible to eradicate the infection permanently in those who possess a tendency for repeated relapses. Consequently, in an effort to unearth a curative drug or regime, it seemed wise to explore the effectiveness of some of the arsenical compounds when used in combination with atabrine.
Although it has been well established that neither neoarsphenamine nor mapharsen has much therapeutic effect in Plasmodium malariae and P. Falciparum infections (1, 2, 3) the use of arsenicals has been recommended from time to time for the treatment of P. vivax infections, particularly the chronic type (4).